[Skip to Content]
Scientist explains drug development, with guest Jason Horton, PhD, on Upstate's "The Informed Patient" podcast

Only a fraction of possible cancer medicines gain final approval

The majority of the promising new cancer drug candidates never make it to market. Only a small fraction of drugs that make it through clinical trials will end up with FDA approval. Jason Horton, PhD, explains some of the pitfalls and tells about potential advances that could speed up the process. Horton is an assistant professor of cell and developmental biology, orthopedic surgery and radiation oncology at Upstate.